---
title: "GENOR-B signs GB261 licensing agreement with TRC 2004, INC"
description: "GENOR-B has entered into a licensing agreement with TRC 2004, INC. for GB261. According to the agreement, GENOR-B will grant the licensee global exclusive rights to develop and utilize GB261. In excha"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/210681600.md"
published_at: "2024-08-04T23:10:03.000Z"
---

# GENOR-B signs GB261 licensing agreement with TRC 2004, INC

> GENOR-B has entered into a licensing agreement with TRC 2004, INC. for GB261. According to the agreement, GENOR-B will grant the licensee global exclusive rights to develop and utilize GB261. In exchange for the license, GENOR-B will receive equity, upfront payment, milestone payments, and royalties from the licensee. GB261 is a novel T-cell receptor agonist with superior safety and efficacy. The collaboration with the licensee will primarily focus on exploring the potential of GB261 in autoimmune diseases

According to the news from Zhitong Finance and Economics APP, GENOR-B (06998) announced that the group entered into a licensing agreement and an equity agreement with TRC 2004, Inc. (the licensee) on August 2, 2024. TRC 2004, Inc. is a company jointly established by Two River, LLC (Two River) and Third Rock Ventures in Delaware, United States. Under the licensing agreement, the group has agreed to grant the licensee global exclusive license (excluding mainland China, Hong Kong, Macau, and Taiwan) to develop, use, manufacture, commercialize, and otherwise exploit GB261.

As part of the consideration for the license, the group will receive a significant amount of equity in the licensee; tens of millions of US dollars upfront payment; milestone payments of up to $443 million; and tiered royalties ranging from single to double-digit percentages of net sales.

It is reported that GB261 is a novel differentiated CD20/CD3 bispecific T cell engager (TCE) with ultra-low CD3 binding affinity and intact Fc function (ADCC and CDC). The company has previously successfully completed Phase 1/2 multicenter studies for B-NHL (DLBCL and FL) in China and Australia. The results have demonstrated excellent safety and efficacy. For example, compared to other similar compounds, GB261 has been shown to significantly reduce cytokine release syndrome (CRS). The characteristics of GB261 make it a very promising B cell depleting agent, with potential indications beyond oncology and applicable to various immunological and autoimmune diseases with significant unmet medical needs in patients. The collaboration with the licensee will mainly focus on exploring the potential of GB261 in autoimmune diseases

### Related Stocks

- [06998.HK - EDDING GENOR](https://longbridge.com/en/quote/06998.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Edding Genor Group Holdings Repurchases 7,855,500 Shares for HKD 1,450 in HKEX Filing | Edding Genor Group Holdings Ltd. has repurchased 7,855,500 shares for a total of HKD 1,450, as disclosed in a filing wit | [Link](https://longbridge.com/en/news/275613176.md) |
| Shootin' the Bull about wave 5 of 5 of B | Shootin' the Bull about wave 5 of 5 of B | [Link](https://longbridge.com/en/news/276266924.md) |
| CICC Reaffirms Their Buy Rating on Suzhou Ribo Life Science Co., Ltd. Class H (6938) | In a report released yesterday, from CICC maintained a Buy rating on Suzhou Ribo Life Science Co., Ltd. Class H, with a  | [Link](https://longbridge.com/en/news/276199846.md) |
| Ence To Cut 44 Jobs At Navia Biofactory By 2027 | Ence Energia y Celulosa SA :REACHES AGREEMENT ON COLLECTIVE DISMISSAL AT NAVIA BIOFACTORYAGREEMENT INCLUDES TERMINATION  | [Link](https://longbridge.com/en/news/276430844.md) |
| Metabiomed To Cancel 2.7 Billion Won Worth Of Own Shares | Metabiomed Co Ltd :METABIOMED: TO CANCEL 2.7 BILLION WON WORTH OF OWN SHARES | [Link](https://longbridge.com/en/news/276408478.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
